120 related articles for article (PubMed ID: 38567475)
21. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.
Hagiwara A; Oughourlian TC; Cho NS; Schlossman J; Wang C; Yao J; Raymond C; Everson R; Patel K; Mareninov S; Rodriguez FJ; Salamon N; Pope WB; Nghiemphu PL; Liau LM; Prins RM; Cloughesy TF; Ellingson BM
Neuro Oncol; 2022 Jun; 24(6):1020-1028. PubMed ID: 34865129
[TBL] [Abstract][Full Text] [Related]
22. Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients.
Heo SH; Shin SS; Kim JW; Lim HS; Jeong YY; Kang WD; Kim SM; Kang HK
Korean J Radiol; 2013; 14(4):616-25. PubMed ID: 23901319
[TBL] [Abstract][Full Text] [Related]
23. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
[TBL] [Abstract][Full Text] [Related]
24. Normalized Apparent Diffusion Coefficient in the Prognostication of Patients with Glioblastoma Multiforme.
Shankar JJ; Bata A; Ritchie K; Hebb A; Walling S
Can J Neurol Sci; 2016 Jan; 43(1):127-33. PubMed ID: 26786643
[TBL] [Abstract][Full Text] [Related]
25. The Potential Role of Peritumoral Apparent Diffusion Coefficient Evaluation in Differentiating Glioblastoma and Solitary Metastatic Lesions of the Brain.
Tepe M; Saylisoy S; Toprak U; Inan I
Curr Med Imaging; 2021; 17(10):1200-1208. PubMed ID: 33726654
[TBL] [Abstract][Full Text] [Related]
26. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
[TBL] [Abstract][Full Text] [Related]
27. Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.
Kong Z; Yan C; Zhu R; Wang J; Wang Y; Wang Y; Wang R; Feng F; Ma W
Neuroimage Clin; 2018; 20():51-60. PubMed ID: 30069427
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.
Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS
J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597
[TBL] [Abstract][Full Text] [Related]
29. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
[TBL] [Abstract][Full Text] [Related]
30. Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.
McDonald CR; Delfanti RL; Krishnan AP; Leyden KM; Hattangadi-Gluth JA; Seibert TM; Karunamuni R; Elbe P; Kuperman JM; Bartsch H; Piccioni DE; White NS; Dale AM; Farid N
Neuro Oncol; 2016 Nov; 18(11):1579-1590. PubMed ID: 27106406
[TBL] [Abstract][Full Text] [Related]
31. Preoperative Apparent Diffusion Coefficient of Peritumoral Lesion Associate with Recurrence in Patients with Glioblastoma.
Matsuda K; Kokubo Y; Kanemura Y; Kanoto M; Sonoda Y
Neurol Med Chir (Tokyo); 2022 Jan; 62(1):28-34. PubMed ID: 34707068
[TBL] [Abstract][Full Text] [Related]
32. Diffusion-weighted imaging: Apparent diffusion coefficient histogram analysis for detecting pathologic complete response to chemoradiotherapy in locally advanced rectal cancer.
Choi MH; Oh SN; Rha SE; Choi JI; Lee SH; Jang HS; Kim JG; Grimm R; Son Y
J Magn Reson Imaging; 2016 Jul; 44(1):212-20. PubMed ID: 26666560
[TBL] [Abstract][Full Text] [Related]
33. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma.
Pope WB; Lai A; Mehta R; Kim HJ; Qiao J; Young JR; Xue X; Goldin J; Brown MS; Nghiemphu PL; Tran A; Cloughesy TF
AJNR Am J Neuroradiol; 2011 May; 32(5):882-9. PubMed ID: 21330401
[TBL] [Abstract][Full Text] [Related]
34. Lymphomas and glioblastomas: differences in the apparent diffusion coefficient evaluated with high b-value diffusion-weighted magnetic resonance imaging at 3T.
Doskaliyev A; Yamasaki F; Ohtaki M; Kajiwara Y; Takeshima Y; Watanabe Y; Takayasu T; Amatya VJ; Akiyama Y; Sugiyama K; Kurisu K
Eur J Radiol; 2012 Feb; 81(2):339-44. PubMed ID: 21129872
[TBL] [Abstract][Full Text] [Related]
35. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
[TBL] [Abstract][Full Text] [Related]
36. Cluster Analysis of DSC MRI, Dynamic Contrast-Enhanced MRI, and DWI Parameters Associated with Prognosis in Patients with Glioblastoma after Removal of the Contrast-Enhancing Component: A Preliminary Study.
Chung H; Seo H; Choi SH; Park CK; Kim TM; Park SH; Won JK; Lee JH; Lee ST; Lee JY; Hwang I; Kang KM; Yun TJ
AJNR Am J Neuroradiol; 2022 Nov; 43(11):1559-1566. PubMed ID: 36175084
[TBL] [Abstract][Full Text] [Related]
37. Risk stratification of ductal carcinoma in situ using whole-lesion histogram analysis of the apparent diffusion coefficient.
Kim JY; Kim JJ; Lee JW; Lee NK; Lee G; Kang T; Park H; Son YH; Grimm R
Eur Radiol; 2019 Feb; 29(2):485-493. PubMed ID: 30073498
[TBL] [Abstract][Full Text] [Related]
38. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
[TBL] [Abstract][Full Text] [Related]
39. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
[TBL] [Abstract][Full Text] [Related]
40. Glioblastoma radiomics to predict survival: Diffusion characteristics of surrounding nonenhancing tissue to select patients for extensive resection.
Pasquini L; Di Napoli A; Napolitano A; Lucignani M; Dellepiane F; Vidiri A; Villani V; Romano A; Bozzao A
J Neuroimaging; 2021 Nov; 31(6):1192-1200. PubMed ID: 34231927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
